Baseline prostate atrophy is associated with reduced risk of prostate cancer in men undergoing repeat prostate biopsy.

INTRODUCTION - We evaluated whether presence and severity of baseline prostate atrophy among men with initial negative biopsy for prostate cancer (PCa) was associated the risk of subsequent PCa detection in a clinical trial with scheduled study-mandated biopsies.

METHODS - Retrospective analysis of 3084 men 50-75 years-old with prostate-specific antigen between 2.5-10ng/mL and a prior negative biopsy from the placebo arm of the Reduction by Dutasteride of PCa Events study who completed at least one per-protocol biopsy. PCa (defined as present or absent) and prostate atrophy (graded as absent, mild or moderate/marked) were assessed by central pathology review. The association of baseline atrophy with positive 2- and 4-year repeat biopsies was evaluated with logistic regression controlling for baseline covariates.

RESULTS - Baseline prostate atrophy was detected in 2143 (70%) and graded as mild, moderate/marked in 1843 (60%) and 300 (10%) baseline biopsies, respectively. Patients with atrophy were older and had larger prostates and more acute and chronic prostate inflammation. At 2-year biopsy, PCa incidence was 17% (N=508). Baseline atrophy was significantly associated with lower PCa risk (multivariable OR=0.60, 95%CI=0.50-0.74 and OR=0.67, 95%CI=0.54-0.83, P<0.001, respectively) at the 2-year biopsy. These results were similar at the 4-year biopsy (OR=0.70, 95%CI=0.53-0.93; OR=0.72, 95%CI=0.53-0.97, P=0.03, respectively uni- and multivariable). Relative to no atrophy, PCa risk at the 2-year repeat biopsy was lower for both mild (OR=0.69, 95%CI=0.55-0.86, P<0.001) and moderate/marked atrophy (OR=0.51, 95%CI=0.34-0.76, P<0.001).

CONCLUSIONS - Baseline prostate atrophy among men with a negative prostate biopsy for PCa was independently associated with subsequent lower PCa detection.

J Urol. 2015 Jul 9. pii: S0022-5347(15)04325-6. doi: 10.1016/j.juro.2015.05.103. [Epub ahead of print]

Moreira DM1, Bostwick DG2, Andriole GL3, Peterson BL4, Cohen HJ5, Castro-Santamaria R6, Freedland SJ7.

1 Department of Urology, Mayo Clinic, Rochester, MN.
2 Bostwick Laboratories, Inc.
3 Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
4 Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.
5 Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
6 GlaxoSmithKline Inc., Global R&D Unit, King of Prussia, Pennsylvania, PA, USA.
7 Division of Urology, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA, USA; Urology Section, Veterans Affairs Medical Center, Durham, NC, USA.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe